SCHEMBL5418554

SCHEMBL5418554

C=CCNC(=O)c1ccccc1-c1ccccc1C(=O)N(CCC(=O)O)CCc1cc(OC)ccc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
KDM4E B2RXH2 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MAPK8 P45983 1/20 0.42
HSD17B10 Q99714 1/20 0.42
RAB9A P51151 1/20 0.41
PKM P14618 2/20 0.40
HTT P42858 2/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
MAPT P10636 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5402706 0.90 MAPT (0.46) KDM4ETDP1ALDH1A1HPGDMAPT
SCHEMBL5403729 0.89 RAB9A (0.52) TAS1R3TAS1R1KDM4EMAPK8HSD17B10
SCHEMBL5399253 0.89 TAS1R3 (0.56) TAS1R3TAS1R1KDM4EMAPK8RAB9A
SCHEMBL5393037 0.88 TAAR1 (0.46) TAS1R3TAS1R1KDM4ERAB9AMAPT
SCHEMBL4925143 0.88 TAS1R3 (0.50) TAS1R3TAS1R1KDM4EMAPK8RAB9A
SCHEMBL5409220 0.86 TDP1 (0.48) KDM4ETDP1RAB9APKMALDH1A1
SCHEMBL5393968 0.86 RAB9A (0.60) TAS1R3TAS1R1KDM4EMAPK8RAB9A
SCHEMBL5405969 0.86 TAS1R3 (0.51) TAS1R3TAS1R1MAPK8RAB9APKM
SCHEMBL5406651 0.86 RAB9A (0.53) KDM4ETDP1RAB9AALDH1A1HPGD
SCHEMBL5407111 0.86 PLAAT3 (0.43) KDM4EALDH1A1HPGDMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB TAS1R3 4642/4885TAS1R1 4377/4885KDM4E 4680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.